Clostridium botulinum infections are caused by clostridium botulinum, a gram-positive, rod-shaped bacterium which produces an extremely lethal substance that is botulism neurotoxin. The spread of clostridium botulinum in human body leads to life-threatening neuroparalysis and can be deadly. It blocks the motor nerve terminal at the myoneural junction and causes flaccid paralysis.
Based on geography, the clostridium botulinum infections market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America holds a leading position in the market followed by Europe. The major factors which are driving the growth of clostridium botulinum infections market in these regions are increasing segment of the people who acquire clostridium botulinum infection, growing awareness about various toxic bacteria, and shift to sophisticated treatment tools. According to Centers for Disease Control and Prevention (CDC), in the U.S., approximately 145 cases of clostridium botulinum infection are reported each year, of which 15% are foodborne, 65% are infant botulism and 20% are wound botulism. Asia Pacific is considered to be the most promising market for the growth of clostridium botulinum infections market followed by Europe. The factors which would propel the growth of the market in Asia Pacific are presence of large population density in countries such as China, India and Brazil, where there is high prevalence of bacterial diseases, favorable reimbursement scenario for treatments and medications, tax benefits and huge government support to set up healthcare infrastructures such as hospitals and research clinics.
Some of the top players operating in clostridium botulinum infections market are DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., Molecular Targeting Technologies, Inc. and many others.
No comments:
Post a Comment